menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging Options in Osteoporosis

close
Emerging Options in Osteoporosis
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.

Facebook Comments

Programs 4/23/21